Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
April 07 2017 - 7:30AM
Business Wire
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical
company focused on delivering innovative therapies to patients with
kidney disease through the biology of hypoxia-inducible factor
(HIF), today announced that the Company granted five newly
hired employees options to purchase an aggregate of 34,000 shares
of the Company's common stock with a per share exercise price of
$9.20, the closing price on the grant date. These options will vest
as to 25% of the total number of shares subject to the option on
the first anniversary of the grant date. The remaining 75% of
shares will vest ratably on the first day of each calendar quarter
over the next three years. The stock options were inducements
material to these new employees entering into employment with the
Company, and issued in reliance on NASDAQ Listing Rule
5635(c)(4).
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company
headquartered in Cambridge, Massachusetts, focused on delivering
innovative therapies to patients with kidney disease through
hypoxia-inducible factor biology. Akebia’s lead product candidate,
vadadustat, is an investigational oral therapy in development for
the treatment of anemia related to chronic kidney disease in both
non-dialysis and dialysis patients. Akebia’s global Phase 3 program
for vadadustat, which includes the PRO2TECT studies for
non-dialysis patients with anemia secondary to chronic kidney
disease and the INNO2VATE studies for dialysis-dependent patients,
is currently ongoing. For more information, please visit our
website at www.akebia.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170407005246/en/
Akebia:Theresa McNeely, 617-844-6113SVP, Corporate
Communicationsand Investor Relationstmcneely@akebia.com
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Sep 2023 to Sep 2024